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A central challenge in designing and administering effective anticoagulants is achieving the proper 
therapeutic window and dosage for each patient. The Hill coefficient, nH, which measures the steepness 
of a dose-response relationship, may be a useful gauge of this therapeutic window. We sought to 
measure the Hill coefficient of available anticoagulants to gain insight into their therapeutic windows. 
We used a simple fluorometric in vitro assay to determine clotting activity in platelet poor plasma after 
exposure to various concentrations of anticoagulants. The Hill coefficient for argatroban was the lowest, 
at 1.7 ± 0.2 (95% confidence interval, CI), and the Hill coefficient for fondaparinux was the highest, at 
4.5 ± 1.3 (95% CI). Thus, doubling the dose of fondaparinux from its IC50 would decrease coagulation 
activity by nearly a half, whereas doubling the dose of argatroban from its IC50 would decrease 
coagulation activity by merely one quarter. These results show a significant variation among the Hill 
coefficients, suggesting a similar variation in therapeutic windows among anticoagulants in our assay.
Traditional anticoagulants such as warfarin require specific dosing for individuals that can be difficult to achieve 
due in part to a narrow therapeutic window and a pharmacological response that varies greatly from patient to 
patient1,2. A response that is too high may cause hemorrhage, whereas a response that is too low would not pro-
vide sufficient antithrombotic benefit.
Recently, selective inhibitors of factor Xa and IIa have become available, and these may have wider thera-
peutic windows as well as less variable pharmacokinetics and pharmacodynamics than warfarin3. These include 
direct thrombin inhibitors such as dabigatran and argatroban; direct factor Xa inhibitors such as apixaban and 
rivaroxaban; and a synthetic pentasaccharide, fondaparinux. However, a careful side-by-side comparison of the 
therapeutic windows of these classes of drugs has not been performed.
Here, we consider how one aspect of the dose-response relationship, known as the Hill coefficient or nH, may 
indicate the drug’s therapeutic window. The Hill coefficient is a measure of the steepness of a dose-response curve, 
with greater nH implying a steeper response4 (Fig. 1). In the case of anticoagulants acting on the coagulation cas-
cade, a high Hill coefficient implies that a small change in the concentration relative to the half-maximal inhibi-
tory concentration (IC50) can cause a large change in the ability to form a clot. In particular, for an anticoagulant 
with nH = 3, maintaining activity within ± 10% of half-maximal activity requires that the drug concentration 
vary at most ~15% from the IC50. In comparison, for nH = 1, maintaining activity within ± 10% of half-maximal 
activity allows for the drug concentration vary ~40% from the IC50 (Fig. 1). Because pharmacokinetic variation 
can cause the level of a drug in plasma to vary, a drug with a large Hill coefficient would be expected to cause a 
more variable response from patient to patient, and a drug with a small Hill coefficient would be expected to have 
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a more consistent response and a wider therapeutic window2,5. Thus, even if two drugs have the same IC50, one 
drug may have a wider therapeutic window if its dose-response curve has a lower Hill coefficient.
Measuring dose-response curves can be difficult and time-consuming. Traditional in vitro methods of mon-
itoring the activity of the clotting cascade, such as measuring the International Normalized Ratio, are not able to 
assess the activity of the network as a whole. On the other hand, monitoring the clotting cascade in vivo is techni-
cally challenging. Therefore, we developed a high-throughput fluorometric assay for thrombin activity, based on 
similar work from other groups6–9. We used this assay to systematically determine the dose-response relationships 
and Hill coefficients of five selective anticoagulants in platelet poor plasma.
Results and Discussion
We found that our system was able to adequately capture the dynamics of thrombin generation. We supplemented 
platelet poor plasma with Z-Gly-Gly-Arg-aminomethylcoumarin (Z-GGR-AMC), which releases fluorescent 
AMC upon cleavage by thrombin. We initiated coagulation by adding Ca2+ and tissue factor, and then we moni-
tored AMC fluorescence over time. A set of 12 time courses of dimethyl sulfoxide (DMSO)-treated control wells 
is displayed in Fig. 2A. Following the addition of Ca2+ and 100 pM lipidated tissue factor, there was a lag phase of 
about 15 minutes during which the cascade had been triggered, but no detectable thrombin had been generated. 
The lag phase was followed by an explosive growth in the amount of AMC fluorescence (and therefore thrombin) 
generated, which continued to rise until its peak at around 170 minutes. After the peak, the fluorescence decayed 
slowly, presumably due to photobleaching effects. These data show that our assay successfully reproduced the 
coagulation cascade in an in vitro, high throughput assay format.
Subsequently, we determined the dose-response relationships of five different anticoagulants: two 
thrombin-selective inhibitors (argatroban and dabigatran) and three factor Xa-selective inhibitors (fondaparinux, 
apixaban, and rivaroxaban). We used the maximum level of fluorescence reached over the entire time course in 
order to compare thrombin activity at different drug doses, including DMSO-treated controls. In order to deter-
mine the Hill coefficient, we fit a Hill curve to the data. These data and the results of the modeling are shown in 
Fig. 2B–F and summarized in Table 1. Although the plots show only a portion of the dose-response curve for 
clarity, all drugs span the entire dynamic range from the baseline control level to essentially no AMC fluorescence 
produced. The best-fit Hill curves are shown in red, and the Hill coefficients ranged from 1.7 ± 0.2 (95% CI) for 
argatroban to 4.5 ± 1.3 for fondaparinux. Thus, doubling the dose of fondaparinux from its IC50 would lead to a 
large 46% decrease in coagulation activity, whereas doubling the dose of argatroban from its IC50 would lead to a 
decrease of 26%, about half the size. This implies that the therapeutic window of argatroban may be significantly 
greater than that of fondaparinux.
Our method applies a classical enzymatic analysis to develop a novel and rapid method for comparing 
the therapeutic windows of anticoagulants in plasma. In the context of route of administration, these results 
are of differing importance for each of these drugs. Some medications are given orally, on a regular basis, 
while others are administered intravenously. For example, fondaparinux is often administered intravenously10, 
but can sometimes be given orally in low doses11. Rivaroxaban is administered orally for initial treatment of 
venous thromboembolism and secondary prevention after acute coronary syndromes. A major challenge with 
rivaroxaban and others of similar administrative routes and chemical composition (like dabigitran and apax-
iban, also evaluated in this paper) is keeping the maximum plasma concentration (Cmax) below a level with a 
high bleeding risk, while keeping the minimum plasma concentration (Ctrough) high enough to be effective12. 
Our results provide new insight for predicting these outcomes. We have shown that there is an approximately 
three-fold variation in the Hill coefficient among the five anticoagulants tested. This implies that certain anti-
coagulants could have a significantly wider “sweet spot” for delivering a beneficial bleeding risk/antithrom-
botic benefit ratio.
Our study indicates that some drugs may be more beneficial than others, depending on clinical and patient 
circumstances. Argatroban and dabigitran have smaller confidence intervals around the Hill coefficient and less 
severe consequences for increasing the dose. Perhaps medication that meets these criteria should be considered 
Figure 1. Simulation of anticoagulant dose and coagulation activity in relation to Hill coefficients and 
therapeutic window. Three simulations with nH = {1,2,3} of the dose-response relationship of a hypothetical 
anticoagulant with fixed IC50 and dynamic range. In order to maintain a coagulation activity of 50 ± 10%, the 
dose of the anticoagulant may vary 83% of the IC50 for nH = 1, but it may only vary 27% of the IC50 for nH = 3.
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above others, and drugs that have a shorter and more severe decline might be more appropriate for more acute 
treatment. For example, argatroban has a wide window (Fig. 2B) which has implications for administration, espe-
cially since this drug is given intravenously to stroke patients13,14.
Figure 2. Dose-response curves show variation in Hill coefficient across various anticoagulants.  
(A) A set of 12 control (DMSO-treated) time courses of thrombin activity versus time in platelet poor plasma 
supplemented with the fluorogenic substrate Z-GGR-AMC and triggered to coagulate using calcium and 
relipidated tissue factor are shown. Curves are partially opaque; darker portions of the plot indicate the overlap 
of more than one curve. (B–F) The peak fluorescence of each time course at the specified drug concentration are 
plotted as a function of concentration of (B) argatroban, (C) dabigatran, (D) rivaroxaban, (E) apixaban, and  
(F) fondaparinux. Each dose-response curve was fitted to the Hill equation, and these curves are shown in 
red for thrombin inhibitors (B,C) and blue for factor Xa inhibitors (D–F). (G) The dose-response curves for 
all drugs is plotted on the same axes and rescaled to have the same IC50, maximum coagulation activity, and 
minimum coagulation activity in order to compare the differences in the therapeutic windows.
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Additional factors can influence choice of anticoagulant. For instance, because dabigitran is eliminated via the 
kidneys, poor kidney function must be considered for deciding drug and dosage15. Furthermore, the experiments 
in this study were conducted on blood without the presence of additional drugs, whereas patients taking antico-
agulants are likely to also take additional medications. When taken concomitantly, the plasma concentration of 
the anticoagulants may change significantly. Our analysis suggests that anticoagulants with lower Hill coefficients 
will be more resilient to this type of drug interaction. Study of these drugs in clinical settings are necessary to 
determine whether this is indeed the case. Indeed, the use of the Hill coefficient as an indicator of therapeutic 
window should be evaluated in further modeling studies and with experiments in vitro and in vivo.
Materials and Methods
In vitro assay for thrombin activity. ~100 ml of blood was withdrawn from Dr. Nicholas Tatonetti (N.P.T.) 
via venipuncture into a standard syringe, and then expelled into tubes with final concentration of 0.011 M sodium 
citrate and 50 mg/ml corn trypsin inhibitor (SCAT-27-45/50SC, Haematologic Technologies Inc.). Whole blood 
was immediately processed into platelet poor plasma as follows. Tubes were centrifuged at 2900 × g for 20 minutes 
in an Eppendorf 5810 R table top centrifuge. The supernatant was slowly and carefully removed by pipetting with 
a trimmed P1000 pipette tip and then transferred into fresh 50 ml screw-top tubes (Corning 430828). These tubes 
were again centrifuged at 290 × g. The supernatant was removed as before, placed into fresh 50 ml tubes, mixed by 
inversion several times, aliquoted into 15 ml screw-top tubes (Corning 430790), and then frozen by placing into 
a − 80 °C freezer for storage. Before use, aliquots were thawed by immersion in a 37 °C water bath until the tube 
temperature reached at least room temperature.
Dabigatran (S2196), Rivaroxaban (S3002), and Apixaban (S1593) were purchased from Selleckchem; 
Fondaprinux sodium (114870-03-0) was purchased from BOC Sciences; and Argatroban monohydrate (A0487-
5MG) was purchased from Sigma-Aldrich. All were diluted to 1 mM and 10 mM stock solutions in DMSO.
In order to monitor thrombin activity, 200 μ M final concentration of Z-GGR-AMC (Bachem 4002155) 
was first added to thawed platelet poor plasma from above. 18 μ L of this solution was plated into each well of a 
384-well plate using a Matrix WellMate 8-channel Microplate Dispenser. Drugs at the desired concentrations and 
the appropriate amount of DMSO normalization was added to each well using an HP D300 Digital Dispenser. 
Finally, 1 μ L of a solution of 400 mM Ca2+ and 100 pM tissue factor (from a lyophilized stock resuspended in 
2.6 mM phosphatidylcholine and 2.6 mM phosphatidylserine to 371 nM recombinant tissue factor, RLTF-0350, 
Haematologic Technologies Inc.) was added using a FlexDrop PLUS Precision Reagent Dispenser to each well to 
trigger coagulation. After five minutes, the plate was immediately transferred to an Envision 2104-0010 Multilabel 
Plate Reader to monitor the amount of AMC present at each time (excitation 346 nm and emission 443 nm using 
a monochromator).
Data analysis. Data was prepared using custom Python scripts. Curve fitting of dose-response data to the 
Hill equation was performed in Mathematica (Wolfram).
Ethics. All methods were carried out in accordance with the protocol, which was reviewed and approved by 
the Columbia University Medical Center Institutional Review Board (IRB-AAAQ3001). Informed consent was 
obtained from all subjects.
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